Do analysts rate GTBP or IMMP?

Prima BioMed has a consensus price target of $5.50, indicating a potential upside of 1,298.42%. Given Prima BioMed's stronger consensus rating and higher probable upside, analysts plainly believe Prima BioMed is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Prima BioMed 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, GTBP or IMMP?

GT Biopharma has higher earnings, but lower revenue than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GT Biopharma N/A N/A -$28.35M -$6.33 N/A Prima BioMed $6.69M 8.66 -$39.78M N/A N/A

Is GTBP or IMMP more profitable?

Company Net Margins Return on Equity Return on Assets GT Biopharma N/A N/A -102.03% Prima BioMed N/A N/A N/A

Do analysts rate GTBP or CNTX?

Context Therapeutics has a consensus target price of $6.17, indicating a potential upside of 1,223.89%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Context Therapeutics is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Context Therapeutics 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70

Which has better valuation and earnings, GTBP or CNTX?

Context Therapeutics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GT Biopharma N/A N/A -$28.35M -$6.33 N/A Context Therapeutics N/A N/A -$36.12M -$0.48 N/A

Is GTBP or CNTX more profitable?

GT Biopharma's return on equity of 0.00% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets GT Biopharma N/A N/A -102.03% Context Therapeutics N/A -82.06% -72.74%

Does the media prefer GTBP or CNTX?

In the previous week, Context Therapeutics had 12 more articles in the media than GT Biopharma. MarketBeat recorded 15 mentions for Context Therapeutics and 3 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 0.64 beat Context Therapeutics' score of 0.19 indicating that GT Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Context Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer INKT or GTBP?

MiNK Therapeutics presently has a consensus price target of $35.00, suggesting a potential upside of 211.80%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe MiNK Therapeutics is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, INKT or GTBP?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiNK Therapeutics N/A N/A -$12.49M -$2.84 N/A GT Biopharma N/A N/A -$28.35M -$6.33 N/A

Is INKT or GTBP more profitable?

Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -118.57% GT Biopharma N/A N/A -102.03%

Does the media favor INKT or GTBP?

In the previous week, MiNK Therapeutics had 4 more articles in the media than GT Biopharma. MarketBeat recorded 7 mentions for MiNK Therapeutics and 3 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 0.64 beat MiNK Therapeutics' score of 0.46 indicating that GT Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer GTBP or INO?

Inovio Pharmaceuticals has a consensus target price of $3.25, suggesting a potential upside of 324.39%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Inovio Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Is GTBP or INO more profitable?

GT Biopharma's return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets GT Biopharma N/A N/A -102.03% Inovio Pharmaceuticals N/A -489.79% -95.40%

Does the media prefer GTBP or INO?

In the previous week, GT Biopharma and GT Biopharma both had 3 articles in the media. GT Biopharma's average media sentiment score of 0.64 beat Inovio Pharmaceuticals' score of 0.58 indicating that GT Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inovio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate GTBP or ATYR?

aTyr Pharma has a consensus target price of $17.00, suggesting a potential upside of 3,083.52%. Given aTyr Pharma's stronger consensus rating and higher possible upside, analysts clearly believe aTyr Pharma is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25

Is GTBP or ATYR more profitable?

GT Biopharma's return on equity of 0.00% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets GT Biopharma N/A N/A -102.03% aTyr Pharma N/A -88.95% -65.31%

Does the media prefer GTBP or ATYR?

In the previous week, aTyr Pharma had 4 more articles in the media than GT Biopharma. MarketBeat recorded 7 mentions for aTyr Pharma and 3 mentions for GT Biopharma. aTyr Pharma's average media sentiment score of 0.95 beat GT Biopharma's score of 0.64 indicating that aTyr Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive aTyr Pharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

GT Biopharma (GTBP) Competitors

$0.31 -0.01 (-2.43%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$0.31 0.00 (-1.53%)

As of 08/11/2026 07:01 PM Eastern

Compare

GTBP vs. IMMP, CNTX, INKT, INO, and ATYR

Should you buy GT Biopharma stock or one of its competitors? GT Biopharma's main competitors and comparable companies include Prima BioMed (IMMP), Context Therapeutics (CNTX), MiNK Therapeutics (INKT), Inovio Pharmaceuticals (INO), and aTyr Pharma (ATYR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does GT Biopharma compare to Prima BioMed?

GT Biopharma (NASDAQ:GTBP) and Prima BioMed (NASDAQ:IMMP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

GT Biopharma has higher earnings, but lower revenue than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A
Prima BioMed	$6.69M	8.66	-$39.78M	N/A	N/A

Prima BioMed has a consensus price target of $5.50, indicating a potential upside of 1,298.42%. Given Prima BioMed's stronger consensus rating and higher probable upside, analysts plainly believe Prima BioMed is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, GT Biopharma had 1 more articles in the media than Prima BioMed. MarketBeat recorded 3 mentions for GT Biopharma and 2 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 1.44 beat GT Biopharma's score of 0.64 indicating that Prima BioMed is being referred to more favorably in the news media.

Company	Overall Sentiment
GT Biopharma	Positive
Prima BioMed	Positive

GT Biopharma has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market.

8.1% of GT Biopharma shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 1.2% of GT Biopharma shares are owned by insiders. Comparatively, 3.1% of Prima BioMed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	N/A	-102.03%
Prima BioMed	N/A	N/A	N/A

Summary

Prima BioMed beats GT Biopharma on 8 of the 11 factors compared between the two stocks.

How does GT Biopharma compare to Context Therapeutics?

GT Biopharma (NASDAQ:GTBP) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

GT Biopharma has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market.

Context Therapeutics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A

Context Therapeutics has a consensus target price of $6.17, indicating a potential upside of 1,223.89%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Context Therapeutics is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, Context Therapeutics had 12 more articles in the media than GT Biopharma. MarketBeat recorded 15 mentions for Context Therapeutics and 3 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 0.64 beat Context Therapeutics' score of 0.19 indicating that GT Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Context Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

8.1% of GT Biopharma shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 1.2% of GT Biopharma shares are owned by insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

GT Biopharma's return on equity of 0.00% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	N/A	-102.03%
Context Therapeutics	N/A	-82.06%	-72.74%

Summary

Context Therapeutics beats GT Biopharma on 9 of the 13 factors compared between the two stocks.

How does GT Biopharma compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and GT Biopharma (NASDAQ:GTBP) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of GT Biopharma shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 1.2% of GT Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
GT Biopharma	N/A	N/A	-102.03%

MiNK Therapeutics has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

MiNK Therapeutics presently has a consensus price target of $35.00, suggesting a potential upside of 211.80%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe MiNK Therapeutics is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

MiNK Therapeutics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A

In the previous week, MiNK Therapeutics had 4 more articles in the media than GT Biopharma. MarketBeat recorded 7 mentions for MiNK Therapeutics and 3 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 0.64 beat MiNK Therapeutics' score of 0.46 indicating that GT Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MiNK Therapeutics beats GT Biopharma on 8 of the 13 factors compared between the two stocks.

How does GT Biopharma compare to Inovio Pharmaceuticals?

GT Biopharma (NASDAQ:GTBP) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

8.1% of GT Biopharma shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 1.2% of GT Biopharma shares are held by company insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

GT Biopharma has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

In the previous week, GT Biopharma and GT Biopharma both had 3 articles in the media. GT Biopharma's average media sentiment score of 0.64 beat Inovio Pharmaceuticals' score of 0.58 indicating that GT Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inovio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GT Biopharma has higher earnings, but lower revenue than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A
Inovio Pharmaceuticals	$60K	1,050.04	-$84.95M	-$1.45	N/A

GT Biopharma's return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	N/A	-102.03%
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%

Inovio Pharmaceuticals has a consensus target price of $3.25, suggesting a potential upside of 324.39%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Inovio Pharmaceuticals beats GT Biopharma on 9 of the 13 factors compared between the two stocks.

How does GT Biopharma compare to aTyr Pharma?

GT Biopharma (NASDAQ:GTBP) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

8.1% of GT Biopharma shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 1.2% of GT Biopharma shares are held by insiders. Comparatively, 5.8% of aTyr Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, aTyr Pharma had 4 more articles in the media than GT Biopharma. MarketBeat recorded 7 mentions for aTyr Pharma and 3 mentions for GT Biopharma. aTyr Pharma's average media sentiment score of 0.95 beat GT Biopharma's score of 0.64 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
aTyr Pharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

GT Biopharma has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

aTyr Pharma has a consensus target price of $17.00, suggesting a potential upside of 3,083.52%. Given aTyr Pharma's stronger consensus rating and higher possible upside, analysts clearly believe aTyr Pharma is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

GT Biopharma's return on equity of 0.00% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	N/A	-102.03%
aTyr Pharma	N/A	-88.95%	-65.31%

GT Biopharma has higher earnings, but lower revenue than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A
aTyr Pharma	$190K	275.68	-$74.12M	-$0.62	N/A

Summary

aTyr Pharma beats GT Biopharma on 11 of the 15 factors compared between the two stocks.

Get GT Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GTBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GTBP vs. The Competition

Export

Metric	GT Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.22M	$3.71B	$7.08B	$12.96B
Dividend Yield	N/A	3.76%	2.57%	10.34%
P/E Ratio	-0.05	10.37	268.43	25.05
Price / Sales	N/A	1,285.89	596.97	89.39
Price / Cash	21.43	102.54	72.26	50.42
Price / Book	1.36	17.98	13.21	6.18
Net Income	-$28.35M	-$13.23M	$3.44B	$347.05M
7 Day Performance	-1.48%	3.20%	2.09%	1.25%
1 Month Performance	-26.40%	-1.17%	-0.23%	-0.64%
1 Year Performance	-82.12%	59.41%	70.30%	20.12%

GT Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GTBP GT Biopharma	0.2748 of 5 stars	$0.31 -2.4%	N/A	-82.0%	$14.22M	N/A	N/A	8	Upcoming Earnings Gap Up
IMMP Prima BioMed	2.3201 of 5 stars	$0.39 +2.5%	$5.50 +1,310.3%	-76.9%	$57.47M	$6.69M	N/A	2,021	Positive News Short Interest Decrease
CNTX Context Therapeutics	2.9542 of 5 stars	$0.62 +2.8%	$6.17 +893.3%	-31.2%	$57.04M	N/A	N/A	7	Earnings Report Analyst Revision Gap Up
INKT MiNK Therapeutics	3.2127 of 5 stars	$11.17 +4.5%	$35.00 +213.3%	-8.1%	$55.63M	N/A	N/A	30	Upcoming Earnings
INO Inovio Pharmaceuticals	2.4248 of 5 stars	$0.67 -4.2%	$3.25 +386.9%	-46.8%	$54.92M	$60K	N/A	320	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GTBP) was last updated on 8/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GT Biopharma (GTBP) Competitors

GTBP vs. IMMP, CNTX, INKT, INO, and ATYR

How does GT Biopharma compare to Prima BioMed?

Summary

How does GT Biopharma compare to Context Therapeutics?

Summary

How does GT Biopharma compare to MiNK Therapeutics?

Summary

How does GT Biopharma compare to Inovio Pharmaceuticals?

Summary

How does GT Biopharma compare to aTyr Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP vs. The Competition

GT Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GT Biopharma (GTBP) Competitors

GTBP vs. IMMP, CNTX, INKT, INO, and ATYR

How does GT Biopharma compare to Prima BioMed?

Which has higher earnings and valuation, GTBP or IMMP?

Do analysts rate GTBP or IMMP?

Does the media favor GTBP or IMMP?

Which has more volatility and risk, GTBP or IMMP?

Do institutionals and insiders hold more shares of GTBP or IMMP?

Is GTBP or IMMP more profitable?

Summary

How does GT Biopharma compare to Context Therapeutics?

Which has more risk and volatility, GTBP or CNTX?

Which has better valuation and earnings, GTBP or CNTX?

Do analysts rate GTBP or CNTX?

Does the media prefer GTBP or CNTX?

Do insiders & institutionals believe in GTBP or CNTX?

Is GTBP or CNTX more profitable?

Summary

How does GT Biopharma compare to MiNK Therapeutics?

Do insiders and institutionals hold more shares of INKT or GTBP?

Is INKT or GTBP more profitable?

Which has more risk and volatility, INKT or GTBP?

Do analysts prefer INKT or GTBP?

Which has preferable earnings and valuation, INKT or GTBP?

Does the media favor INKT or GTBP?

Summary

How does GT Biopharma compare to Inovio Pharmaceuticals?

Do insiders & institutionals hold more shares of GTBP or INO?

Which has more risk & volatility, GTBP or INO?

Does the media prefer GTBP or INO?

Which has preferable earnings and valuation, GTBP or INO?

Is GTBP or INO more profitable?

Do analysts prefer GTBP or INO?

Summary

How does GT Biopharma compare to aTyr Pharma?

Do institutionals & insiders hold more shares of GTBP or ATYR?

Does the media prefer GTBP or ATYR?

Which has more risk and volatility, GTBP or ATYR?

Do analysts rate GTBP or ATYR?

Is GTBP or ATYR more profitable?

Which has better earnings & valuation, GTBP or ATYR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP vs. The Competition

GT Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools